Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM)
119.49
+14.72 (14.05%)
NASDAQ · Last Trade: Dec 11th, 3:17 PM EST
Detailed Quote
Previous Close
104.77
Open
113.73
Bid
119.36
Ask
119.62
Day's Range
111.00 - 122.20
52 Week Range
45.90 - 116.00
Volume
2,556,684
Market Cap
7.97B
PE Ratio (TTM)
-38.55
EPS (TTM)
-3.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
684,585
Chart
About Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM)
Rhythm Pharmaceuticals Inc. is a biopharmaceutical company focused on transforming the treatment paradigm for people with rare metabolic disorders, particularly those related to obesity and appetite regulation. The company is dedicated to advancing its research and development efforts to create therapies that target the underlying causes of these conditions. By leveraging innovative science and its expertise in the genetic basis of obesity, Rhythm aims to develop effective treatments that improve the quality of life for patients and address significant unmet medical needs in the field of metabolic health. Read More
-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy --
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Thursday, December 11 at 8:00 a.m. ET to disclose preliminary data from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS).
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy –
IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHB
Rhythm Pharmaceuticals posts mixed Q3 2025 results, missing revenue estimates. Despite the loss, the company highlights strong drug growth and key regulatory milestones for its obesity treatments.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update.
BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences:
Rhythm Pharmaceuticals Q2 2025 results show revenue beat but EPS miss, causing a 5.7% pre-market drop. Regulatory progress for setmelanotide remains on track.
